Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs

NYSE:PFE

Pfizer Inc (PFE)

28.06
+0.09 (0.32%)
as of Aug 25, 2026, 2:11:02 pm Market Open.
582 watching
0
Investor Insights
star iconAug 25, 2026, 12:00 am

This summary was created by AI, based on 24 opinions in the last 12 months.

Pfizer Inc. (PFE) is facing significant challenges as it navigates a patent cliff following the success of its COVID-19 vaccine. Many experts are concerned about its ability to generate new blockbuster drugs and the sustainability of its high dividend yields, which currently range from 6.4% to 7%. Several reviews emphasize that while the dividend is attractive, the company lacks earnings momentum and has uncertainty surrounding its drug pipeline. The stock trades at low earnings multiples, suggesting it may be undervalued, but experts warn that the lack of growth drivers could limit upside potential. Overall, patience may be required for investors looking for signs of recovery or growth in the company's future, especially as its recent acquisitions are yet to yield significant results.

consensus icon
Consensus
Neutral
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
HOLD
Good merger made. Good company.
BUY
Positive on the drug industry.
BUY
Strong pipeline. Republican win is good for pharmaceuticals.
BUY
Should start to see a rise.
BUY
Top quality company. Cheap. Good sector for the long term.
BUY
Sector has been hit hard. A very liquid stock.
DON'T BUY
Governments are trying to cut health care costs. Sector seems to be weak.
BUY
US pharmaceutical sector is very cheap now.
TOP PICK
Trading at less than 20 X earnings. Reasonable dividend yield. Have some new products in the pipeline.
BUY
Looks good.
TOP PICK
Likes the valuations. Good balance sheet and good earnings. Made some good acquisitions.
HOLD
Fair market value is more than share price.
BUY
Now is a good time for drug stocks.
BUY
At a good level now.
BUY
Earnings growth is sustainable.
Showing 796 to 810 of 887 entries